Two Sigma Investments
TRML

Two Sigma Investments’s Tourmaline Bio TRML Stock Holding History

Two Sigma Investments’s Portfolio TRML Stock Details TRML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-36,643
Closed -$557K – 3548
2025
Q1 		$557K Buy
36,643
+15,202
+71% +$244K ﹤0.01% 2478
2024
Q4 		$435K Sell
21,441
-21,904
-51% -$552K ﹤0.01% 2590
2024
Q3 		$1.11M Sell
43,345
-119,889
-73% -$2M ﹤0.01% 2059
2024
Q2 		$2.1M Buy
163,234
+138,687
+565% +$2.23M ﹤0.01% 1518
2024
Q1 		$562K Sell
24,547
-31,816
-56% -$1.12M ﹤0.01% 2277
2023
Q4 		$1.48M Buy
56,363
+31,760
+129% +$636K ﹤0.01% 1827
2023
Q3 		$691K Buy
24,603
+1,961
+9% +$57.4K ﹤0.01% 2133
2023
Q2 		$688K Buy
22,642
+19,886
+722% +$508K ﹤0.01% 2172
2023
Q1 		$51.8K Sell
2,756
-7,711
-74% -$127K ﹤0.01% 2750
2022
Q4 		$107K Buy
10,467
+6,949
+198% +$112K ﹤0.01% 2498
2022
Q3 		$93K Buy
+3,518
New +$128K ﹤0.01% 2241
2021
Q4 		– Sell
-1,080
Closed -$146K – 4903
2021
Q3 		$146K Sell
1,080
-3,417
-76% -$468K ﹤0.01% 4029
2021
Q2 		$661K Buy
+4,497
New +$689K ﹤0.01% 2855

Other funds holding TRML

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return

Two Sigma Investments's TRML Position: Q2 2025 in Review

Two Sigma Investments sold out of Tourmaline Bio (TRML) in Q2 2025, closing a stake of 36,643 shares — an estimated $557K sold.

Two Sigma Investments first reported a position in TRML in Q2 2021 and held it in 13 quarters. The position peaked at $2.1M in Q2 2024. 108 funds tracked by Wall St. Rank hold TRML as of Q2 2025.

  • Two Sigma Investments reported no remaining Tourmaline Bio position as of Q2 2025 after selling out during the quarter.
  • Two Sigma Investments sold 36,643 Tourmaline Bio shares in Q2 2025, an estimated $557K.
  • Two Sigma Investments first reported a position in Tourmaline Bio in Q2 2021 and held it in 13 quarters.
  • Two Sigma Investments's Tourmaline Bio position peaked at $2.1M in Q2 2024.
  • 108 funds tracked by Wall St. Rank held Tourmaline Bio as of Q2 2025.

Based on Two Sigma Investments's 13F filing for Q2 2025, filed 14 Aug 2025.